FDA Panel To Assess Trial Design As It Reviews Teva's Azilect To Delay Progression Of Parkinson's
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reviewers identify numerous issues with analyses and results of ADAGIO trial.